Literature DB >> 25731965

Incidence and predictors of severe acute esophagitis and subsequent esophageal stricture in patients treated with accelerated hyperfractionated chemoradiation for limited-stage small cell lung cancer.

Jonathan D Grant1, Shervin M Shirvani2, Chad Tang1, Aditya Juloori3, Neal C Rebueno1, Pamela K Allen1, Joe Y Chang4.   

Abstract

PURPOSE: Clinical and dosimetric predictors of severe (grade 3 or greater) acute esophageal toxicity and subsequent esophageal dilation were explored in patients with limited-stage small cell lung cancer treated with accelerated hyperfractionated chemoradiation. METHODS AND MATERIALS: A total of 130 patients were identified who were treated to 45 Gy in 1.5-Gy twice-daily fractions with concurrent platinum-based chemotherapy between 2000 and 2009. Data on clinical, disease-related, and treatment-related variables were collected. Patients with percutaneous endoscopic gastrostomy tube insertion or intravenous hydration because of poor oral intake were designated as having acute grade 3 esophagitis. Univariate and multivariate analyses that associated treatment characteristics with esophagitis were assessed via logistic regression, and optimal cut points were identified with recursive partitioning analysis.
RESULTS: Twenty-five patients developed severe acute esophagitis, at a rate of 26% (18/69) in patients treated with earlier 3-dimensional conformal radiation therapy techniques and 11.5% (7/61) in patients treated with intensity modulated radiation therapy techniques and omission of elective nodal irradiation. The incidence of esophageal stricture was 6% overall (8 of 128 eligible) but 26% (6/23) among those who experienced prior grade 3 acute esophagitis and 2% (2/105) among those with acute esophagitis less than or equal to grade 2. Significant multivariate predictors of acute esophagitis were mean dose and volume of esophagus receiving at least 5% to 35% of the prescribed dose (V5 to V40). Patients with V5 ≥ 74% had a 44.4% risk of severe acute esophagitis (12/27) versus 12.6% (13/103) among those with V5 < 74%. V45 was the only dosimetric predictor for esophageal stricture, with 13.7% of patients in whom V45 was ≥37.5% requiring subsequent dilation.
CONCLUSIONS: Modern radiation techniques are associated with a lower frequency of severe acute esophagitis than previous paradigms. The proportion of esophagus receiving low- to moderate-range doses (mean, V5 through V40) predicts acute esophagitis, whereas the proportion of esophagus that receives high doses (V45) predicts the development of esophageal stricture that requires dilation. Patients who develop grade 3 acute esophagitis are at significant risk for subsequent esophageal stricture, whereas those with acute esophagitis of grade 2 or less display minimal risk.
Copyright © 2015 American Society for Radiation Oncology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 25731965     DOI: 10.1016/j.prro.2015.01.005

Source DB:  PubMed          Journal:  Pract Radiat Oncol        ISSN: 1879-8500


  3 in total

Review 1.  Advances in dosimetry and biological predictors of radiation-induced esophagitis.

Authors:  Yang Yu; Hui Guan; Yuanli Dong; Ligang Xing; Xiaolin Li
Journal:  Onco Targets Ther       Date:  2016-01-28       Impact factor: 4.147

2.  Carbon-ion Radiotherapy for Isolated Lymph Node Metastasis After Surgery or Radiotherapy for Lung Cancer.

Authors:  Katsuyuki Shirai; Yoshiki Kubota; Tatsuya Ohno; Jun-Ichi Saitoh; Takanori Abe; Tatsuji Mizukami; Yasumasa Mori; Hidemasa Kawamura; Keiko Akahane; Takashi Nakano
Journal:  Front Oncol       Date:  2019-08-07       Impact factor: 6.244

3.  Severe esophageal stenosis in a patient with metastatic colon cancer following palliative radiotherapy, ramucirumab, and chemotherapy.

Authors:  Keiko Akahane; Katsuyuki Shirai; Masaru Wakatsuki; Kazunari Ogawa; Kyosuke Minato; Kohei Hamamoto; Satoru Takahashi; Koichi Suzuki; Jun Takahashi; Toshiki Rikiyama; Keita Matsumoto; Hirosato Mashima
Journal:  Clin Case Rep       Date:  2020-03-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.